Compare Stocks: ATAI, AXSM, RDY, and CRNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.35	$6.94	$3.27 ▼ $7.45	$2.73B	1.54	13.29 million shs	N/A
AXSM Axsome Therapeutics	$220.75 +4.6%	$220.65	$112.90 ▼ $260.19	$11.56B	0.71	535,585 shs	1.23 million shs
CRNX Crinetics Pharmaceuticals	$84.95	$83.44	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
RDY Dr. Reddy's Laboratories	$11.91 +1.7%	$12.35	$11.36 ▼ $15.67	$9.93B	0.28	2.47 million shs	3.14 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	+0.26%	-0.54%	+1.38%	+87.50%	+55.72%
AXSM Axsome Therapeutics	0.00%	+6.81%	+3.31%	-13.49%	+77.85%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	+0.60%	+146.45%	+142.71%
RDY Dr. Reddy's Laboratories	0.00%	-0.53%	-4.18%	-10.51%	-18.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.35	$6.94	$3.27 ▼ $7.45	$2.73B	1.54	13.29 million shs	N/A
AXSM Axsome Therapeutics	$220.75 +4.6%	$220.65	$112.90 ▼ $260.19	$11.56B	0.71	535,585 shs	1.23 million shs
CRNX Crinetics Pharmaceuticals	$84.95	$83.44	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
RDY Dr. Reddy's Laboratories	$11.91 +1.7%	$12.35	$11.36 ▼ $15.67	$9.93B	0.28	2.47 million shs	3.14 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	+0.26%	-0.54%	+1.38%	+87.50%	+55.72%
AXSM Axsome Therapeutics	0.00%	+6.81%	+3.31%	-13.49%	+77.85%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	+0.60%	+146.45%	+142.71%
RDY Dr. Reddy's Laboratories	0.00%	-0.53%	-4.18%	-10.51%	-18.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Beckley	2.06	Hold	$10.56	43.62% Upside
AXSM Axsome Therapeutics	2.91	Moderate Buy	$267.60	21.22% Upside
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-4.65% Downside
RDY Dr. Reddy's Laboratories	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest ATAI, AXSM, RDY, and CRNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	CRNX Crinetics Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/31/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$290.00
8/24/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	AXSM Axsome Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	AXSM Axsome Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/17/2026	ATAI Atai Beckley	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/13/2026	ATAI Atai Beckley	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	AXSM Axsome Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$306.00 ➝ $316.00
8/12/2026	ATAI Atai Beckley	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$12.00 ➝ $8.00
8/12/2026	ATAI Atai Beckley	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$12.00 ➝ $8.00
8/11/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$304.00 ➝ $297.00

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Beckley	$4.09M	666.46	N/A	N/A	$0.69 per share	10.65
AXSM Axsome Therapeutics	$638.50M	18.11	N/A	N/A	$1.75 per share	126.14
CRNX Crinetics Pharmaceuticals	$7.70M	1,170.54	N/A	N/A	$11.23 per share	7.56
RDY Dr. Reddy's Laboratories	$3.58B	2.78	$0.85 per share	14.05	$4.86 per share	2.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Beckley	-$660.05M	-$2.18	N/A	N/A	N/A	-14,938.36%	-88.30%	-58.88%	11/12/2026 (Estimated)
AXSM Axsome Therapeutics	-$183.17M	-$3.75	N/A	54.37	N/A	-24.68%	-265.55%	-28.10%	11/2/2026 (Estimated)
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	11/5/2026 (Estimated)
RDY Dr. Reddy's Laboratories	$456M	$0.44	25.32	20.89	2.48	10.15%	9.49%	6.32%	10/23/2026 (Estimated)

Latest ATAI, AXSM, RDY, and CRNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ATAI Atai Beckley	-$0.1075	-$0.09	+$0.0175	-$0.09	$0.60 million	$1.70 million
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	-$0.99	-$0.0980	-$0.99	$221.11 million	$218.38 million
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million
7/23/2026	Q1 26/27	RDY Dr. Reddy's Laboratories	$0.0918	$0.06	-$0.0318	$0.06	$850.56 million	$850.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Beckley	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.06	0.50%	+6.96%	13.64%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Beckley	N/A	N/A	N/A
AXSM Axsome Therapeutics	1.52	1.43	1.34
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
RDY Dr. Reddy's Laboratories	0.03	1.90	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Beckley	28.41%
AXSM Axsome Therapeutics	81.49%
CRNX Crinetics Pharmaceuticals	98.51%
RDY Dr. Reddy's Laboratories	3.85%

Insider Ownership

Company	Insider Ownership
ATAI Atai Beckley	19.80%
AXSM Axsome Therapeutics	20.60%
CRNX Crinetics Pharmaceuticals	3.80%
RDY Dr. Reddy's Laboratories	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Beckley	80	370.86 million	297.43 million	Optionable
AXSM Axsome Therapeutics	925	52.38 million	41.59 million	Optionable
CRNX Crinetics Pharmaceuticals	210	106.10 million	102.06 million	Optionable
RDY Dr. Reddy's Laboratories	27,527	834.67 million	817.98 million	Optionable

ATAI, AXSM, RDY, and CRNX Headlines

Recent News About These Companies

Wellington Management Group LLP Cuts Position in Dr. Reddy's Laboratories Ltd $RDY

September 12 at 4:23 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 8, 2026 | globenewswire.com

Nykredit A S Takes $2 Million Position in Dr. Reddy's Laboratories Ltd $RDY

September 8, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 3, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 1, 2026 | globenewswire.com

Dr. Reddy's Laboratories (NYSE:RDY) Upgraded to Hold at Wall Street Zen

August 29, 2026 | marketbeat.com

Dr. Reddy's Laboratories Ltd $RDY Shares Sold by Bank of America Corp DE

August 28, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

August 27, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

August 25, 2026 | globenewswire.com

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 19, 2026 | tmcnet.com

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 19, 2026 | businesswire.com

RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

August 13, 2026 | businesswire.com

Dr. Reddy's Laboratories Ltd. Sponsored ADR

August 12, 2026 | cnn.com

Dr. Reddy's Laboratories Launches Sugammadex Injection Single-Dose Vials in US

August 5, 2026 | finance.yahoo.com

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

August 5, 2026 | globenewswire.com

Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of ...

August 4, 2026 | finance.yahoo.com

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

August 4, 2026 | businesswire.com

Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky

July 31, 2026 | prnewswire.com

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy's Laboratories (RDY)

July 29, 2026 | globenewswire.com

Dr Reddys Laboratories Ltd (RDY)

July 28, 2026 | insidermonkey.com

Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...

July 28, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI, AXSM, RDY, and CRNX Company Descriptions

Atai Beckley NASDAQ:ATAI

$7.35 0.00 (0.00%)

As of 09/11/2026

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Axsome Therapeutics NASDAQ:AXSM

$220.75 +9.63 (+4.56%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$220.50 -0.25 (-0.11%)

As of 09/11/2026 07:52 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.95 0.00 (0.00%)

As of 09/1/2026

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Dr. Reddy's Laboratories NYSE:RDY

$11.91 +0.20 (+1.67%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$11.90 -0.01 (-0.09%)

As of 09/11/2026 07:30 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATAI, AXSM, RDY, and CRNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATAI, AXSM, RDY, and CRNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATAI, AXSM, RDY, and CRNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI, AXSM, RDY, and CRNX Company Descriptions

Atai Beckley NASDAQ:ATAI

Axsome Therapeutics NASDAQ:AXSM

Crinetics Pharmaceuticals NASDAQ:CRNX

Dr. Reddy's Laboratories NYSE:RDY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATAI, AXSM, RDY, and CRNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATAI, AXSM, RDY, and CRNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATAI, AXSM, RDY, and CRNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI, AXSM, RDY, and CRNX Company Descriptions

Atai Beckley NASDAQ:ATAI

Axsome Therapeutics NASDAQ:AXSM

Crinetics Pharmaceuticals NASDAQ:CRNX

Dr. Reddy's Laboratories NYSE:RDY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools